PRLD - Prelude Therapeutics EPS misses by $0.02 November, 12 2021 08:35 AM Prelude Therapeutics Incorporated Prelude Therapeutics (NASDAQ:PRLD): Q3 GAAP EPS of -$0.66 misses by $0.02. Cash, cash equivalents, and marketable securities of $320.9M. Press Release For further details see: Prelude Therapeutics EPS misses by $0.02